2023-10-06T17:22:20Z
2023-10-06T17:22:20Z
2023-06-15
2023-09-05T12:51:56Z
Simple Summary The treatment of retroperitoneal sarcomas poses significant challenges due to their infrequency, clinical and histologic heterogeneity, and unique anatomical location. We provide an updated review on the management of retroperitoneal sarcoma and issue clear and concise recommendations for the treatment of the main clinical situations encountered in this disease. Soft tissue sarcomas (STS) are an uncommon and biologically heterogeneous group of tumors arising from mesenchymal cells. The incidence is estimated at five cases per 100,000 people per year. Retroperitoneal sarcomas (RPS) account for 10-15% of all STS, and their management depends on their anatomical characteristics and histotype. Due to their very low incidence, it is recommended that RPS be treated in reference centers and evaluated by an experienced multidisciplinary team (MDT). In Spain, the Spanish Group for Research in Sarcomas (GEIS) brings together experts from various specialties to promote research on sarcomas and improve treatment results. This paper summarizes the GEIS recommendations for the diagnosis, treatment, and follow-up of patients with RPS.
Article
Versió publicada
Anglès
Sarcoma; Tumors de parts toves; Medicina clínica; Diagnòstic; Sarcoma; Soft tissue tumors; Clinical medicine; Diagnosis
MDPI AG
Reproducció del document publicat a: https://doi.org/10.3390/cancers15123194
Cancers, 2023, vol. 15, num. 12, p. 3194
https://doi.org/10.3390/cancers15123194
cc by (c) Álvarez Álvarez, Rosa et al., 2023
http://creativecommons.org/licenses/by/3.0/es/